Elicio Therapeutics (ELTX) Shares Outstanding (Weighted Average) (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $18.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 40.63% year-over-year to $18.2 million; the trailing twelve-month figure through Mar 2026 stood at $18.2 million (up 40.63% YoY), and the FY2025 full-year result was $15.3 million, up 25.48% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $18.2 million, up from $15.3 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $30.0 million in Q1 2022 and bottomed at $314572.0 in Q2 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $10.8 million (2024), against an average of $9.9 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) tumbled 98.94%; it then surged 3069.93% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $315998.0 in 2022, then surged by 1500.08% to $5.1 million in 2023, then soared by 141.35% to $12.2 million in 2024, then increased by 25.48% to $15.3 million in 2025, then climbed by 18.93% to $18.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $18.2 million (Q1 2026), $15.3 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.

Peer Comparison